尿路悪性腫瘍に対する腎被膜下移植法(Subrenal capsule assay)による制癌剤感受性試験

概要

論文の詳細を見る
泌尿器科領域の悪性腫瘍を中心に47例に腎被膜下移植法による制癌剤感受性試験を行った.1) 41例が評価可能で,全体で13薬剤について166回の感受性試験が行われ,47回が陽性であった.2)腎細胞癌では16例中10例に感受性を示す薬剤を認め,60回中14回が陽性を示し,VP-16, ADM, BLM, 5-FUで30%以上の症例で感受性が認められた.3)尿路上皮癌では10例中8例に感受性を示す薬剤を認め,41回中14回が陽性を示し,CDDP, VP-16, UFTで30%以上の症例で感受性が認められたWe evaluated the subrenal capsule assay with a chemosensitivity test using 47 fresh surgical explants, including 16 renal cell carcinomas and 10 uroepithelial cancers. Forty-one explants were evaluable and 166 drug tests were performed. Forty-seven tests (28.3%) were found to be sensitive. Ten of 16 renal cell carcinomas involved a sensitive drug, 3 involved more than 2 sensitive drugs. VP-16, ADM, BLM and 5-FU were the most sensitive compared with the others. Concerning the uroepithelial cancers, 8 of 10 involved a sensitive drug, 5 involved more than 2 sensitive drugs. CDDP and VP-16 were more effective than the other drugs. This result showed a good correlation with the clinical therapeutic efficacy using CDDP. In the future, we hope to evaluate the clinical correlation between clinical efficacy and this assay.